August 2026– date –
-
WuXi Advanced Therapies Significantly Expands Cell Therapy Manufacturing Capacity to Meet Surging Client Demand, Reinforcing GMP Capabilities and Process Development
WuXi Advanced Therapies China Overview WuXi Advanced Therapies announced a substantial expansion of its cell therapy manufacturing facilities. This significant investment aims to address the growing demand from clients for complex cell t... -
Hitachi Drives Industrialization of Cell Therapies with AI-Powered Manufacturing Innovation
Hitachi Japan Overview Hitachi has initiated a new collaboration with prominent research institutions to advance innovative cell processing technologies. This partnership is designed to significantly enhance the efficiency and scalabilit... -
Lonza Reports Robust Cell and Gene Therapy Sector Growth in H1 2026 Earnings, Driven by CDMO Contracts and Facility Utilization
Lonza Switzerland Overview Lonza announced strong growth in its cell and gene therapy division in the first half of 2026 earnings, propelled by an increase in new CDMO contracts and improved utilization of existing manufacturing faciliti... -
Catalent Enhances End-to-End Cell and Gene Therapy Services to Accelerate Market Entry of Novel Therapeutics
Catalent USA Overview Catalent has significantly bolstered its comprehensive, end-to-end service portfolio in the cell and gene therapy sector. This enhancement aims to accelerate the market entry of client therapies by providing seamles... -
Thermo Fisher Scientific Dramatically Expands Global Cell and Gene Therapy CDMO Manufacturing Capacity with Enhanced Automation
Thermo Fisher Scientific USA Overview Thermo Fisher Scientific has significantly expanded its global manufacturing network for cell and gene therapy products to meet surging demand. This strategic move aims to provide advanced manufactur... -
FDA Details Regenerative Medicine Advanced Therapy (RMAT) Designation Framework, Offering Fast Track and Breakthrough Therapy Benefits
Global MedTech Expert USA Overview Global MedTech Expert details the FDA's regulatory framework for 351/361 HCT/P classification and Regenerative Medicine Advanced Therapy (RMAT) designation. RMAT offers significant benefits, including F... -
BioPharma Dive Reports on Cell and Gene Therapy Manufacturing Frontlines: Viral Vector Supply Shortages and CDMO Market Soaring to $9.08 Billion by 2031
BioPharma Dive USA Overview BioPharma Dive analyzes key challenges and commercial opportunities in cell and gene therapy manufacturing, pinpointing viral vector production as the most severe supply constraint. Lonza is significantly expa... -
Liv Hospital Pioneers iPSC-Driven 3D Bioprinting and Organoid Development, Reshaping Organ Transplantation
Liv Hospital Turkey Overview Liv Hospital is at the forefront of research highlighting the pivotal role of induced pluripotent stem cell (iPSC) lines in advancing 3D bioprinting and organoid development. These initiatives aim to engineer... -
Unlocking Exosome Therapies for Corneal Disorders: Overcoming the Clinical Translation Challenge
Annals of Translational Medicine China Overview A recent review in *Annals of Translational Medicine* underscores the significant hurdles facing exosome-based therapies for corneal disorders, primarily in achieving manufacturing standard... -
Gene Editing Startup Race Intensifies: CRISPR Therapeutics Leads in Commercialization, Intellia Advances In Vivo Phase 3, Beam Demonstrates Base Editing Versatility Across Human Therapies
New Market Pitch USA Overview A New Market Pitch analysis reveals CRISPR Therapeutics leads in commercialization with approved therapies, while Intellia Therapeutics shows significant progress in Phase 3 in vivo gene editing trials. Beam...
